Share
1,381 Posts.
lightbulb Created with Sketch. 227
clock Created with Sketch. 29/06/22
11:47
Share
Originally posted by bedger:
↑
Hilarious isn't it? It was with some 'fear' I sold my tech stocks in the US late 2021 with admittedly very poor grasp on measuring exuberance. I just knew they were ridiculously valued, but then again, they were half a year before too! OCC had long been under-valued given its products. Then it started looking a bit shaky with management's ability to commercialise, hence the price falls. I don't know where the 2H 2022 low is in OCC, but I do know its ridiculously under-valued with this deal and these prices.This company has gone from very much from needing a capital raising come year end if they had not negotiated this or another deal, to now having some 15 quarters worth of cash at their present run rate, whilst the revenues from BioHorizons sales moving them towards positive free cash flow anyway and certainly that cash run rate will be signficantly reduced by manufacturing revenues.
Expand
Striate+ has been talked down for years on this site, sure enough it’s the first revenue earner for Orthocell, like most time frames blowing out over the years, this has cause our share price to suffer, management has there first real revenue stream, for a good 25 years, let me say that again
(20min delay)